think you are right about the clown selling.
hiring still taking place.
etrade holding summary shows institutional holdings are on the rise again.
all left are for Bridgewater, NJ
Insmed is seeking qualified candidates for the following positions.
Job Title Department Location
Program Manager - Commercial Finance Bridgewater, NJ
Program (Project) Manager - Technical Operations Finance Bridgewater, NJ
Regulatory Associate Regulatory Affairs Bridgewater, NJ
Associate Director, Quality Assurance - GCP Quality Assurance Bridgewater, NJ
Senior Quality Assurance Specialist/Manager - GCP Quality Assurance Bridgewater, NJ
Biostatistician Medical Affairs Bridgewater, NJ
Director, Clinical Development Clinical Bridgewater, NJ
Receptionist Bridgewater, NJ
Commercial Compliance Counsel Legal Bridgewater, NJ
Marketing Director, Digital Commercialization Bridgewater, NJ
posted June 17 2014 09:56 EDT-----
Leerink biotech analyst holds an analyst/industry conference call
posted June 18 2014 11:17 EDT------
comes from the fly on the wall
this was in yahoo news finance summary yesterday. GONE TODAY!
Insmed Inc. (INSM) provided a spring interim update from the CLEAR-110 study, an ongoing, two-year, open-label extension study of once-daily Arikace, or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa in cystic fibrosis patients. These data are from 98 patients who have completed the first 12 months of the CLEAR-110 extension study. The data were collected as part of a scheduled data safety monitoring board review of the CLEAR-110 extension study. The data showed that Arikace was well tolerated, and there was a sustained improvement from baseline level in forced expiratory volume in one second.
The Leerink team expects an announcement regarding breakthrough status for the drug with huge upside, espe
cially if no Phase 3 study is required. The consensus price target is a stunning $33.40. Insmed closed Tuesday at $13.
estimated release date
from press release march 06 2014
The Company expects to provide additional 2014 cash guidance when it releases first quarter 2014 financial results.
this stock always go down on earnings announcement.
this being a Friday could be a double whammy if earnings are bad and announcement of a share dilution
on same day for someones buddy.
During 2014 the Company plans to continue to fund further clinical development of ARIKAYCE, invest in third-party manufacturing capacity, support efforts to obtain regulatory approvals, and prepare for commercialization. Insmed estimates that its cash requirements to fund operations for the first quarter of 2014 will
be in the range of $15.0 million to $17.0 million. The Company expects to provide additional 2014 cash guidance when it releases first quarter 2014 financial results.